Mereo BioPharma vs Silence Therapeutics
MREO and SLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MREO and SLN compare
Silence Therapeutics scores higher on the StockData Score (6 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MREO | SLN |
|---|---|---|
| Size and price | ||
| Market cap | $246M | – |
| Share price | $0.307 | $19.83 |
| Change, 1 year | −83.3% | 195% |
| Change, 5 years | −84.7% | −13.6% |
| Beta (5Y) | 0.59 | 1.05 |
| Employees | 39 | 88 |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 10.4× | – |
| FCF yield | −9.0% | – |
| Growth | ||
| Revenue growth (TTM) | – | −97.7% |
| Profitability | ||
| Gross margin | – | 85.9% |
| Operating margin | – | −11107% |
| Net margin | – | −9748% |
| FCF margin | – | −6873% |
| Return on equity | −76.6% (better) | −90.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −440.6× | – |
| Current ratio | 5.22 | 7.42 (better) |
| Altman Z-score | −1.99 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 7.1% | 16.6% |
| Held by insiders | 0.18% | 48.1% |
Go deeper
- MREO stock overview
- MREO income statement
- MREO valuation and score
- SLN stock overview
- SLN income statement
- SLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.